Some previous studies have addressed an assessment of the influence of the PD-1/PD-L1/PD-L2 axis markers on the survival of patients with invasive breast cancer, more specifically TNBC, showing discrepant results. This evidence concerns the gene PDCD1LG2 and invasive breast carcinoma.